S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
Log in

NASDAQ:ARWR - Arrowhead Pharmaceuticals Stock Price, Forecast & News

$36.39
-2.10 (-5.46 %)
(As of 02/24/2020 04:00 PM ET)
Today's Range
$35.73
Now: $36.39
$38.10
50-Day Range
$36.39
MA: $46.80
$59.75
52-Week Range
$17.27
Now: $36.39
$73.72
Volume1.67 million shs
Average Volume1.67 million shs
Market Capitalization$3.70 billion
P/E Ratio68.66
Dividend YieldN/A
Beta1.95
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ARWR
CUSIPN/A
Phone626-304-3400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$168.80 million
Cash Flow$0.73 per share
Book Value$2.57 per share

Profitability

Net Income$67.97 million

Miscellaneous

Employees116
Market Cap$3.70 billion
Next Earnings Date5/13/2020 (Estimated)
OptionableOptionable

Receive ARWR News and Ratings via Email

Sign-up to receive the latest news and ratings for ARWR and its competitors with MarketBeat's FREE daily newsletter.


Arrowhead Pharmaceuticals (NASDAQ:ARWR) Frequently Asked Questions

What is Arrowhead Pharmaceuticals' stock symbol?

Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR."

How were Arrowhead Pharmaceuticals' earnings last quarter?

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) issued its quarterly earnings data on Wednesday, February, 5th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.04 by $0.07. The biotechnology company had revenue of $29.46 million for the quarter, compared to analyst estimates of $36.63 million. Arrowhead Pharmaceuticals had a net margin of 32.56% and a return on equity of 18.21%. View Arrowhead Pharmaceuticals' Earnings History.

When is Arrowhead Pharmaceuticals' next earnings date?

Arrowhead Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, May 13th 2020. View Earnings Estimates for Arrowhead Pharmaceuticals.

What price target have analysts set for ARWR?

9 equities research analysts have issued 12 month target prices for Arrowhead Pharmaceuticals' stock. Their forecasts range from $32.00 to $83.00. On average, they anticipate Arrowhead Pharmaceuticals' stock price to reach $64.13 in the next twelve months. This suggests a possible upside of 76.2% from the stock's current price. View Analyst Price Targets for Arrowhead Pharmaceuticals.

What is the consensus analysts' recommendation for Arrowhead Pharmaceuticals?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last year. There are currently 2 sell ratings, 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Arrowhead Pharmaceuticals.

Has Arrowhead Pharmaceuticals been receiving favorable news coverage?

Media coverage about ARWR stock has trended neutral on Monday, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Arrowhead Pharmaceuticals earned a media sentiment score of 0.4 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 9.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for Arrowhead Pharmaceuticals.

Are investors shorting Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals saw a decline in short interest during the month of January. As of January 15th, there was short interest totalling 11,120,000 shares, a decline of 8.9% from the December 31st total of 12,200,000 shares. Based on an average daily trading volume, of 2,270,000 shares, the short-interest ratio is presently 4.9 days. Currently, 12.0% of the shares of the company are short sold. View Arrowhead Pharmaceuticals' Current Options Chain.

Who are some of Arrowhead Pharmaceuticals' key competitors?

What other stocks do shareholders of Arrowhead Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), AbbVie (ABBV), Sarepta Therapeutics (SRPT), Advanced Micro Devices (AMD), salesforce.com (CRM), Bristol-Myers Squibb (BMY) and Bank of America (BAC).

Who are Arrowhead Pharmaceuticals' key executives?

Arrowhead Pharmaceuticals' management team includes the folowing people:
  • Dr. Christopher R. Anzalone, CEO, Pres & Director (Age 50)
  • Mr. Kenneth A. Myszkowski, Chief Financial Officer (Age 53)
  • Dr. Bruce D. Given, Chief Operating Officer (Age 65)
  • Mr. Patrick O'Brien, Gen. Counsel (Age 55)
  • Dr. Mark M. Davis, Founder and Founder & Director of Insert Therapeutics Inc & Calando

Who are Arrowhead Pharmaceuticals' major shareholders?

Arrowhead Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include State Street Corp (4.06%), FMR LLC (1.85%), Geode Capital Management LLC (1.41%), Fiera Capital Corp (1.34%), Bank of New York Mellon Corp (1.05%) and Goldman Sachs Group Inc. (0.86%). Company insiders that own Arrowhead Pharmaceuticals stock include Bruce D Given, Christopher Richard Anzalone, Douglas B Given, Kenneth Allen Myszkowski, Mauro Ferrari, Michael S Perry, Patrick O'brien, Peter Brian Leone, William D Waddill and Zhen Li. View Institutional Ownership Trends for Arrowhead Pharmaceuticals.

Which institutional investors are selling Arrowhead Pharmaceuticals stock?

ARWR stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Farallon Capital Management LLC, Candriam Luxembourg S.C.A., Principal Financial Group Inc., Rafferty Asset Management LLC, Goldman Sachs Group Inc., Oak Ridge Investments LLC and Fiera Capital Corp. Company insiders that have sold Arrowhead Pharmaceuticals company stock in the last year include Bruce D Given, Christopher Richard Anzalone, Douglas B Given, Kenneth Allen Myszkowski, Mauro Ferrari, Michael S Perry and Patrick O'brien. View Insider Buying and Selling for Arrowhead Pharmaceuticals.

Which institutional investors are buying Arrowhead Pharmaceuticals stock?

ARWR stock was purchased by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., FMR LLC, Credit Suisse AG, American International Group Inc., Mutual of America Capital Management LLC, Retirement Systems of Alabama, Geode Capital Management LLC and Man Group plc. View Insider Buying and Selling for Arrowhead Pharmaceuticals.

How do I buy shares of Arrowhead Pharmaceuticals?

Shares of ARWR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Arrowhead Pharmaceuticals' stock price today?

One share of ARWR stock can currently be purchased for approximately $36.39.

How big of a company is Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals has a market capitalization of $3.70 billion and generates $168.80 million in revenue each year. The biotechnology company earns $67.97 million in net income (profit) each year or $0.69 on an earnings per share basis. Arrowhead Pharmaceuticals employs 116 workers across the globe.View Additional Information About Arrowhead Pharmaceuticals.

What is Arrowhead Pharmaceuticals' official website?

The official website for Arrowhead Pharmaceuticals is http://www.arrowheadpharma.com/.

How can I contact Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals' mailing address is 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105. The biotechnology company can be reached via phone at 626-304-3400 or via email at [email protected]


MarketBeat Community Rating for Arrowhead Pharmaceuticals (NASDAQ ARWR)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  446 (Vote Outperform)
Underperform Votes:  420 (Vote Underperform)
Total Votes:  866
MarketBeat's community ratings are surveys of what our community members think about Arrowhead Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARWR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARWR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel